All > Eosinophilic Esophagitis > Maryland

APT-1011 for Eosinophilic Esophagitis

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Eosinophilic EsophagitisAPT-1011 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This is a 24-week randomized, double-blind, placebo-controlled induction study of APT-1011 in adults (≥18 years old) with eosinophilic esophagitis (EoE) followed by a single-arm, open-label extension. This study will evaluate the efficacy and safety of APT-1011 3 mg administered HS (hora somni, at bedtime) for the induction of response to treatment (symptomatic and histologic) over 24 weeks. The open-label extension will continue to evaluate long-term safety in subjects who consent to continue on open-label treatment with APT-1011.

Eligible Conditions
  • Eosinophilic Esophagitis

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Similar Trials

1
Cendakimab
2
AK002
2
Lorcaserin

Study Objectives

2 Primary · 11 Secondary · Reporting Duration: Week 24

Week 24
Clinicopathologic Responder Rate
Complete Symptomatic Response (Co- Measure)
Histological Remission (Co- Measure)
Mean Change in Dysphagia Frequency
Mean Change in EREFs
Mean Change in PROSE Difficulty Swallowing
Mean Change in PROSE Pain with Swallowing
Mean Number of Dysphagia-Free Days
Percentage of Responders (Strictures and ≥Grade 2 rings)
Percentage of Responders (Strictures)
Percentage of Responders (≥Grade 2 rings)
Percentage of Subjects with ≥70% Reduction in Dysphagia Frequency
Time to First Complete Symptom Response

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Similar Trials

1
Cendakimab
3
AK002
3
Lorcaserin

Trial Design

2 Treatment Groups

APT-1011
1 of 2
Placebo
1 of 2

Experimental Treatment

Non-Treatment Group

200 Total Participants · 2 Treatment Groups

Primary Treatment: APT-1011 · Has Placebo Group · Phase 3

APT-1011
Drug
Experimental Group · 1 Intervention: APT-1011 · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo oral tablet · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
APT-1011
2020
Completed Phase 3
~260

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: week 24

Who is running the clinical trial?

Ellodi Pharmaceuticals, LPLead Sponsor
3 Previous Clinical Trials
148 Total Patients Enrolled
3 Trials studying Eosinophilic Esophagitis
148 Patients Enrolled for Eosinophilic Esophagitis
Evan Dellon, MD, MPHPrincipal InvestigatorUNC Center for Esophageal Diseases and Swallowing
2 Previous Clinical Trials
229 Total Patients Enrolled
2 Trials studying Eosinophilic Esophagitis
229 Patients Enrolled for Eosinophilic Esophagitis

Eligibility Criteria

Age 18+ · All Participants · 9 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You will have a central pathologist read your biopsy.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top